Drug adverse event reports (FAERS)

Nasopharyngitis

Drugs: JUBBONTI

Not seriousReport 27325177
Safetyreportversion
1
Safetyreportid
27325177
Primarysourcecountry
US
Occurcountry
US
Transmissiondateformat
102
Transmissiondate
20261010
Reporttype
1
Serious
2
Seriousnessdeath
2
Seriousnesslifethreatening
2
Seriousnesshospitalization
2
Seriousnessdisabling
2
Seriousnesscongenitalanomali
2
Seriousnessother
2
Receivedateformat
102
Receivedate
20260930
Receiptdateformat
102
Receiptdate
20260930
Fulfillexpeditecriteria
2
Companynumb
US-SANDOZ-2026-127518
Duplicate
1
Reportduplicate
Duplicatesource
-
Duplicatenumb
US-00481261-1
Primarysource
Reportercountry
US
Qualification
5
Sender
Sendertype
6
Senderorganization
SANDOZ
Receiver
Receivertype
6
Receiverorganization
FDA
Patient
Patientsex
2
Reaction
  1. Reactionmeddraversionpt
    29.0
    Reactionmeddrapt
    Nasopharyngitis
    Reactionoutcome
    6
Drug
  1. Drugcharacterization
    1
    Medicinalproduct
    JUBBONTI
    Drugseparatedosagenumb
    1
    Drugdosagetext
    JUBBONTI (DENOSUMAB-BBDZ), 60MG INJECTION, FOR SUBCUTANEOUS USE IN PREFILLED SYRINGE
    Drugindication
    Product used for unknown indication
    Actiondrug
    5
    Drugrecurreadministration
    3
    Drugadditional
    3
    Activesubstance
    Activesubstancename
    DENOSUMAB-BBDZ
Wholesale access for licensed clinicians.

Free to join: your NPI is checked against the federal registry at signup, then wholesale pricing and the professional shelves open.

Join as a DoctorSell on MedGrid

How to read this: Each report says someone told FDA an event happened while a product was used. A report does not show the product caused it, and counts rise and fall with how many people report. Data from openFDA, FDA's public API. FDA says not to rely on it to make decisions about medical care and to treat every result as unvalidated; confirm against FDA's own record and the product labeling. Not medical or legal advice.